Announcement • May 23
Alkermes plc Showcases Data from Psychiatry Portfolio and Sleep Research into Real World Patient Experience At Spring 2026 Scientific Conferences
Alkermes plc announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI (olanzapine and samidorphan) and ARISTADA (aripiprazole lauroxil)—and its ongoing involvement in sleep medicine. The data presented reflect Alkermes’ ongoing commitment to contributing to the advancement of patient care and expanding the body of evidence in neuroscience. The meetings included: The Psych Congress NP Institute (NPI), March 19-22, Nashville, Tenn.; American Association of Psychiatric Pharmacists (AAPP) Annual Meeting, April 19-22, Seattle; The Neuroscience Education Institute (NEI) Spring Congress, May 1-3, Kissimmee, Fla.; American Psychiatric Association (APA), May 16-20, San Francisco; The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, May 17-20, Philadelphia. Highlights of accepted presentations include: APA Clinical Trials Plenary presentation showcasing clinical research that expands our understanding of the near-term and long-term effects of LYBALVI and the positive real-world impact of LYBALVI on treatment adherence, treatment persistence, risk of relapse, and effectiveness, including in young adults with schizophrenia or bipolar I disorder. Results of a real-world comparison of LYBALVI versus olanzapine that assessed rates of adherence, persistence, and disease-related inpatient admissions and emergency department visits as proxies for relapse, among adults with schizophrenia or bipolar I disorder. Results of a real-world analysis of disease-related inpatient admissions and emergency department visits, as proxies for relapse, in the 12 months before versus after initiating LYBALVI among young adult patients with schizophrenia or bipolar I disorder. The full list of Alkermes’ presentations by meeting is as follows: NPI: Poster 1: Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia; Poster 2: Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia; Poster 3: Use of an Aripiprazole Lauroxil Injection Administered Once Every Month, 6 Weeks, or 2 Months in People With Schizophrenia: A Clinician-Focused Summary of Study Data; Poster 12: Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data; Poster 13: Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia or Bipolar I Disorder; Poster 14: Importance of Real-World Evidence in Clinical Decision Making. AAPP: Poster 328: Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia; Poster 329: Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia; Poster 336: Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data; Poster 338: Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia or Bipolar I Disorder; Poster 339: Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder. NEI-Spring: Poster 10: Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia; Poster 11: Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia; Poster 21: Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia or Bipolar I Disorder; Poster 26: Olanzapine and Samidorphan in Adults With Schizophrenia or Bipolar I Disorder: Updated Review of Clinical Data. APA: Poster P08-100: Importance of Real-World Evidence in Clinical Decision-Making; Podium Presentation as part of the Clinical Trials Plenary: Olanzapine/Samidorphan Combination (OLZ/SAM) for Patients with Schizophrenia or Bipolar I Disorder. ISPOR: Poster CO95: Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder; Poster CO138: Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia or Bipolar I Disorder; Poster PCR12: Real-World Experience and Burden of Cognitive Impairment in Narcolepsy and Idiopathic Hypersomnia: Survey Results From the ASPIRE Study; Poster PCR52: Real-World Symptoms and Impacts of Narcolepsy and Idiopathic Hypersomnia: Qualitative Results Using Social Media Listening Methods; Poster PCR177: Real-World Experience and Burden of Fatigue in Narcolepsy and Idiopathic Hypersomnia: Survey Results From the ASPIRE Study. LYBALVI (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, in a single bilayer tablet. LYBALVI is available in fixed dosage strengths composed of 10 mg of samidorphan and 5 mg, 10 mg, 15 mg or 20 mg of olanzapine. LYBALVI is indicated for the treatment of: Schizophrenia in adults; Bipolar I disorder in adults; Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate; Maintenance monotherapy treatment. Boxed Warning: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis. Contraindications: LYBALVI is contraindicated in patients who are using opioids or are undergoing acute opioid withdrawal. If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for the contraindications for these products. Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis, including stroke, transient ischemia attack, and fatalities.
